Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J.-C. Roujeau is active.

Publication


Featured researches published by J.-C. Roujeau.


British Journal of Dermatology | 2007

Risk factors for acute generalized exanthematous pustulosis (AGEP)—results of a multinational case–control study (EuroSCAR)

Alexis Sidoroff; Ariane Dunant; Cécile Viboud; Sima Halevy; J.N. Bouwes Bavinck; Luigi Naldi; Maja Mockenhaupt; J-P. Fagot; J.-C. Roujeau

Background  Acute generalized exanthematous pustulosis (AGEP) is a disease characterized by the rapid occurrence of many sterile, nonfollicular pustules usually arising on an oedematous erythema often accompanied by leucocytosis and fever. It is usually attributed to drugs.


British Journal of Dermatology | 2013

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

Sylvia H. Kardaun; Peggy Sekula; Laurence Valeyrie-Allanore; Yvonne Liss; Chia-Yu Chu; Daniel Creamer; Alexis Sidoroff; Luigi Naldi; Maja Mockenhaupt; J.-C. Roujeau

Cases of severe drug hypersensitivity, demonstrating a variable spectrum of cutaneous and systemic involvement, are reported under various names, especially drug reaction with eosinophilia and systemic symptoms (DRESS). Case definition and overlap with other severe cutaneous adverse reactions (SCAR) are debated.


British Journal of Dermatology | 2010

Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.

Laurence Valeyrie-Allanore; P. Wolkenstein; L. Brochard; Nicolas Ortonne; B. Maître; J. Revuz; Martine Bagot; J.-C. Roujeau

Background  Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute mucocutaneous reactions associated with poor prognosis. The treatment is mainly symptomatic, based on supportive care. Until now, several curative treatments have been proposed without evidence of effectiveness.


British Journal of Dermatology | 1997

Drug-induced linear IgA disease: target antigens are heterogeneous

C. Paul; P. Wolkenstein; C. Prost; F. Caux; G. Rostoker; M. Heller; Janine Wechsler; J. Revuz; J.-C. Roujeau

No information is available concerning the target antigen(s) involved in drug‐induced linear IgA disease. The purpose of this study was to define better drug‐induced linear IgA desease by studying its immunopathological, immunoultrastructural and immunochemical characteristics in three patients. In the first patient. IgA deposits were seen in the lamina lucida. In the second and the third patients. IgA deposits were seen on each side of the lamina densa. Immunoblotting of the first patients serum showed that IgA reacted with a protein of 230 kDa similar to the bullous pemphigoid‐associated antigen 1 (BPAG 1). The second patients serum did not react with specific bands. In the third patient IgA antibodies reacted with a protein of 97 kDa on epidermal extracts. Our findings suggest that, as in idiopathic forms, the target antigen is not unique in drug‐induced linear IgA disease. In some patients, drug‐induced linear IgA disease may represent an IgA class response to the BPAG 1.


British Journal of Dermatology | 2013

Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients

C. Hotz; Laurence Valeyrie-Allanore; C. Haddad; Sophie Bouvresse; Nicolas Ortonne; T.-A. Duong; S. Ingen-Housz-Oro; J.-C. Roujeau; P. Wolkenstein; Olivier Chosidow

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterized by rash with sterile pustules, high fever and elevated circulating neutrophil counts.


Dermatology | 2009

Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey

P. Wolkenstein; J. Revuz; J.-C. Roujeau; G. Bonnelye; J.J. Grob; Sylvie Bastuji-Garin

Background: Risk factors for psoriasis have been identified. Objective: To precisely define these associated factors. Methods: A survey was conducted using a questionnaire on a representative sample of the French population. A case-control study was conducted. Cases were persons who declared having had psoriasis during the previous 12 months. For each case, 3 matched controls were selected. Cases and controls were compared using univariate and multivariate analyses. Results: The questionnaire was filled out and returned by 6,887 (68.9%) of 10,000 subjects aged 15 years and over; 356 cases were identified. In multivariate analysis, a higher body mass index, current and former smoking habits and β-blocker intake were independently associated with a higher risk of psoriasis; intake of statins was associated with a decreased risk (p < 0.05). Conclusions: We confirmed the association of overweight, smoking habits and β-blocker intake with psoriasis and reported a decreased risk associated with statin intake.


British Journal of Dermatology | 2013

Linear IgA bullous dermatosis: comparison between the drug‐induced and spontaneous forms

J. Chanal; S. Ingen-Housz-Oro; Nicolas Ortonne; T.-A. Duong; M. Thomas; Laurence Valeyrie-Allanore; B. Lebrun-Vignes; C. André; J.-C. Roujeau; Olivier Chosidow; P. Wolkenstein

Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering skin disorder characterized by linear deposits of IgA along the dermoepidermal junction, visualized by direct immunofluorescence (DIF). It is usually spontaneous and drug induced.


British Journal of Dermatology | 2013

Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.

S. Lipowicz; Peggy Sekula; S. Ingen‐Housz‐Oro; Yvonne Liss; Bruno Sassolas; Ariane Dunant; J.-C. Roujeau; Maja Mockenhaupt

Background  Generalized bullous fixed drug eruption (GBFDE) is a rare cutaneous adverse reaction to drugs, and may resemble Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), but is usually considered less severe.


British Journal of Dermatology | 2000

Amicrobial pustulosis associated with autoimmune diseases: healing with zinc supplementation

N. Bénéton; P. Wolkenstein; Martine Bagot; Cosnes A; Janine Wechsler; J.-C. Roujeau; J. Revuz

Amicrobial pustulosis associated with autoimmune diseases is an eruption involving the cutaneous flexures and scalp. We report two young women with this disease, in whom pustulosis healed with zinc supplementation. We suggest that it may be relevant to measure plasma zinc level in patients with such a disease.


British Journal of Dermatology | 2015

Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study

N. Ortonne; Laurence Valeyrie-Allanore; Sylvie Bastuji-Garin; J. Wechsler; S. de Feraudy; T.-A. Duong; M.-H. Delfau-Larue; Olivier Chosidow; P. Wolkenstein; J.-C. Roujeau

The histopathological features of drug rash with eosinophilia and systemic symptoms (DRESS) syndrome remain poorly characterized.

Collaboration


Dive into the J.-C. Roujeau's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martine Bagot

French Institute of Health and Medical Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge